clinical trial using REGN2810

My wife just finished 4 infusions of gemcitabine and cisplatin over the last 7 weeks. A new CT scan showed her hilar CC mostly unchanged by the chemo. Oncologist suggested radiation and 5FU going forward.
We found a clinical trial at Sarah Cannon institute using REGN2810, which is an anti PD-1 inhibitor much the same as Ketruda. In fact the oncologist said all the PD-1 inhibitors are pretty much the same for as their effectiveness.
It can be combined with radiation and or certain chemo drugs.
Here is a cut and paste about it:
]REGN2810 is a type of drug called a monoclonal antibody. REGN2810 is a fully human monoclonal anti – PD-1 antibody (a type of protein) that works by blocking the programmed death receptor 1 (PD-1), a cell receptor on immune cells that is involved in preventing the immune cells from destroying other cells. Blocking the receptor is expected to help the immune cells attack the cancer cells. This study is being conducted to test the safety of REGN2810 and to see if blocking PD-1 with REGN2810 will help the immune system attack the tumor, and to determine whether combining REGN2810 with radiotherapy and/or cyclophosphamide is safe enough and if it can help to improve tumor shrinkage.

Since this trial has been going on for about a year at several different locations, I was wondering if anyone here ahs any knowledge about it.

Thanks….Ben